Arteris director granted 365 restricted shares

Kunkel Joachim reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kunkel Joachim reported acquisition or exercise transactions in this Form 4 filing.

Arteris, Inc. director Joachim Kunkel reported receiving a grant of 365 shares of common stock as fully vested restricted stock. These shares represent director retainer fees that he chose to take in stock instead of cash, at no cash cost per share. The grant was calculated using an average Arteris trading price of $39.28 over a defined period, and Kunkel elected to defer the actual receipt of the shares, leaving his reported direct holdings at 74,695 shares after the award.

Insider Trade Summary

Grant/Award: 365 shares

Grant/Award 1 txn

Insider Kunkel Joachim

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	365	$0.00	$0.00

Holdings After Transaction: Common Stock — 74,695 shares (Direct)

Footnotes (2)

1. F1. Fully vested restricted stock. The restricted stock represents retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. This grant of restricted stock was made on July 5, 2026, based on the average trading price of Arteris, Inc. common stock for the period from May 20, 2026 through July 2, 2026, which was $39.28.
2. F2. The Reporting Person elected to defer the receipt of shares.

Key Figures

Restricted stock grant: 365 shares Reported grant price: $0.00 per share Holdings after transaction: 74,695 shares +1 more

4 metrics

Restricted stock grant 365 shares Director retainer fees taken in stock

Reported grant price $0.00 per share Compensation grant, not open-market purchase

Holdings after transaction 74,695 shares Direct ownership following award

Average trading price basis $39.28 Average Arteris price from May 20, 2026 to July 2, 2026

Key Terms

restricted stock, retainer fees, defer the receipt of shares

3 terms

restricted stock financial

"Fully vested restricted stock. The restricted stock represents retainer fees that the Reporting Person elected to receive in the form of shares"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

retainer fees financial

"The restricted stock represents retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash"

defer the receipt of shares financial

"The Reporting Person elected to defer the receipt of shares."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Arteris (AIP) director Joachim Kunkel report in this Form 4?

Director Joachim Kunkel reported receiving 365 shares of Arteris common stock as fully vested restricted stock. The shares represent retainer fees he elected to take in stock rather than cash, with his direct holdings reported at 74,695 shares after the grant.

Was Joachim Kunkel’s Arteris (AIP) transaction an open-market purchase or sale?

The transaction was not an open-market trade; it was a grant of restricted stock as compensation. Kunkel received 365 shares at a reported price of $0.00 per share in lieu of cash retainer fees for his director service.

How was the number of Arteris (AIP) shares in Joachim Kunkel’s grant determined?

The 365-share restricted stock grant was based on the average trading price of Arteris common stock of $39.28. This average covered the period from May 20, 2026 through July 2, 2026, and was used to convert cash retainer fees into stock.

Did Joachim Kunkel defer receipt of the Arteris (AIP) restricted stock?

Yes. The filing states that Joachim Kunkel elected to defer the receipt of the shares. This means the award is credited, but the actual delivery of the 365 restricted stock shares will occur at a later time under the deferral terms.

What are Joachim Kunkel’s reported Arteris (AIP) holdings after this Form 4 transaction?

After the reported grant, Kunkel’s total direct holdings are listed as 74,695 shares of Arteris common stock. This figure includes the newly credited 365 restricted stock shares and reflects his position following the compensation-related acquisition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 04:22 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kunkel Joachim

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CALIFORNIA 95008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/05/2026		A		365(1)(2)	A	$0.00	74,695	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Fully vested restricted stock. The restricted stock represents retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. This grant of restricted stock was made on July 5, 2026, based on the average trading price of Arteris, Inc. common stock for the period from May 20, 2026 through July 2, 2026, which was $39.28.

2. The Reporting Person elected to defer the receipt of shares.

Remarks:

	/s/ Paul Alpern, as Attorney-in-Fact for Kunkel Joachim	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)